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The application of animal models to study the biocompat-
ibility of bicarbonate-buffered peritoneal dialysis solutions.
Patients treated with peritoneal dialysis (PD) are at risk for de-
velopment of ultrafiltration failure and peritonitis. These two
significant complications can result in the termination of PD
treatment. The relative unphysiologic composition of the cur-
rently used standard peritoneal dialysis fluids (PDF) is consid-
ered to be a major cause for the development of morphologic
changes of the peritoneal membrane, ultimately resulting in
ultrafiltration failure and probably contributing to changes in
local defense mechanisms with the associated increased risk of
peritonitis. In recent years, a major research focus has become
the development of new and improved PD solutions. This has
resulted in the development of an amino-acid–based PDF, a
glucose polymer–based PDF, and several bicarbonate-buffered
PDF. Typically, the first phase of biocompatibility testing of new
PD solutions involves in vitro testing, employing isolated cells
such as peritoneal macrophages or cell culture systems using
human peritoneal mesothelial cells. The results of such eval-
uations are useful in providing insights into the biocompati-
bility performance of any given formulation, but suffer from
several disadvantages, which can be better addressed using
animal models. In vivo studies using animals permit the analysis
of biocompatibility under conditions that allow for cell-to-cell
interactions and dynamic changes in solution composition that
more closely mimic the clinical situation. In this paper, we will
review the use of animal models for the study of PDF biocom-
patibility and their application to the assessment of bicarbonate-
buffered PDF.
Since the introduction of chronic peritoneal dialy-
sis (PD), it has become widely recognized that alter-
ations in peritoneal membrane structure and function
occur over time, and are thought largely to be due to
prolonged exposure to peritoneal dialysis fluids (PDF).
Observed changes in the membrane include brown-
ish tanning of the parietal peritoneum, detachment of
mesothelial cells or complete loss of the mesothelial cell
monolayer, increased submesothelial extracellular ma-
trix deposition and fibrosis, and extended neovasculariza-
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tion [1–4]. From these observations it can be appreciated
that prolonged exposure to PDF is likely to be responsi-
ble for the anatomic changes of the peritoneal membrane,
and could contribute to the clinical observation of ultra-
filtration failure in patients on long-term PD.
Constituents of currently used conventional PDF that
are considered bioincompatible and contribute to the
development of the morphologic changes of the
peritoneal membrane are the acidic pH, the supraphys-
iologic levels of lactate, the high glucose concentration
and its associated high osmolality, and the presence
of glucose degradation products (GDPs) that result from
heat sterilization of the PDF. In addition to these fac-
tors, the presence of a chronically indwelling PD catheter,
as well as the instillation of large volumes of fluid,
per se, could contribute to the observed membrane
changes.
The effects of biocompatibility factors on cellular phys-
iology have been examined in in vitro studies using res-
ident cell types of the peritoneal cavity. High glucose
concentrations can impair cell survival in leukocytes
and human peritoneal mesothelial cells (HPMCs) [5, 6],
alter the normal pattern of chemokine secretion [7, 8],
and induce the production of potentially angiogenic and
profibrotic growth factors and cytokines [9]. Similar detri-
mental effects have been attributed to the high osmolality
[10, 11], acidity, and high lactate concentration of con-
ventional PDF [10, 12]. It has been demonstrated that
pH neutralization of conventional fluids with NaOH or
bicarbonate, for example, results in a greater preservation
of cellular function [7, 12]. Likewise, it has been shown
that GDPs such as 3-deoxyglucosone and methyl glyoxal
are very reactive substances that can result in the devel-
opment of advanced glycation end products (AGEs) [13]
and impair cell function [6, 9]. While in vitro cell cul-
ture studies can be valuable in investigating the effects of
individual PDF constituents on cellular function and es-
tablishing a baseline for biocompatibility, extrapolation
from these observations to in vivo effects is difficult. Thus,
the application of animal models can have clear advan-
tages over cell culture studies.
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BIOCOMPATIBILITY TESTING
IN ANIMAL MODELS
In order to unravel the pathophysiology of the peri-
toneal membrane under PD conditions in more detail,
it is now generally accepted that experiments in lab-
oratory animals can be very helpful. For example, to
date, five international meetings on animal models in PD
have been convened. Rabbits, rats, and occasionally mice
have all been used to examine the physiologic effects of
exposure to PDF [14]. Today, most research groups se-
lect the rat as the best model for several reasons. Rats
and mice are economical and have robust peritoneal
host defense systems, while rabbits are expensive and
extremely susceptible to peritoneal infection. Moreover,
the availability of many different mouse and rat strains,
including genetically modified murine strains, make these
rodents good candidates for evaluation of PD bio-
compatibility. However, surgical implantation of an in-
dwelling intraperitoneal catheter in combination with
daily instillation of fluids via the catheter is very dif-
ficult in mice because of their small size, thus ren-
dering the rat as the ideal experimental animal in
PD research.
Theoretically, an animal model for PD should mimic
the clinical PD situation as closely as possible, thus com-
bining end-stage renal failure with exchanges of PDF
(i.e., both infusion and drainage of solution) several times
a day. This is technically feasible in the rabbit [15], al-
beit cumbersome to accomplish. Frequent exchanges are
feasible in the rat, but require omentectomy to prevent
catheter occlusion. This procedure, however, renders the
model less physiologic because the omentum plays a cru-
cial role in the local inflammatory response to many stim-
uli, including PDF [16]. Thus, the most popular rat models
used today for the study of PD solution biocompatibility
usually are not dialysis models, per se, but rather rep-
resent peritoneal infusion models that allow the study
of peritoneal response to chronic PDF exposure. Addi-
tionally, the most appropriate or representative animal
model should combine a uremic animal, (e.g., by subtotal
nephrectomy) with a chronically dialyzed PD model, but
this has not yet been widely employed.
Which criteria should an exposure model fulfill to make
it a suitable model for studying PDF-induced changes
of the peritoneal membrane? First, it is important that
the PDF can be instilled into the peritoneum on daily
basis for an extended period via a catheter, similar to
that performed in patients. This requires an indwelling
catheter because daily intraperitoneal injection by pierc-
ing the peritoneal wall results in peritoneal activation
that can hinder the clear identification of PDF-induced
peritoneal alterations. Second, intraperitoneal instilla-
tion of the PDF must be performed in a sterile fash-
ion. This is best achieved by connecting the intraperi-
toneal catheter to a subcutaneously placed access port,
avoiding the use of a percutaneous access device. Subcu-
taneous ports avoid damage to the catheter and subse-
quent risk of infection caused by the freely moving rat.
Third, the instillation of PDF should be done without any
additives like heparin or antibiotics to avoid confound-
ing variables in the model. Finally, whereas most groups
studying the effects of PDF on the peritoneal membrane
use an exposure model, many differences between the
models exist. These include differences in fill volumes,
number of fills per day, time of exposure to PDF, and
addition of additives like heparin and antibiotics. These
variations should be considered when comparing stud-
ies and interpreting results. Notwithstanding, these dif-
ferences, the application of animal models has increased
our knowledge of the effects of PDF on the peritoneal
membrane.
PERITONEAL CHANGES INDUCED BY
CHRONIC EXPOSURE TO CONVENTIONAL PDF
Many different groups now have investigated the peri-
toneal response to chronic PDF exposure and have
reported on histologic, immunologic, and functional (i.e.,
transport) changes. Histologic and immunologic changes
will now be reviewed.
Histologic changes
The major histologic changes observed after PDF
exposure include: (1) an increase in vessel number;
(2) enhanced fibrosis and formation of granulation tissue;
and (3) damage to and regeneration of the mesothelial
cell layer. We and others have shown that chronic daily
instillation of conventional PDF yields an angiogenic re-
sponse in the omentum, mesentery, liver surface, and
parietal peritoneal wall [17–19]. In addition, we have
demonstrated by electron microscopy a clear thickening
of the endothelial cell layer, which is suggestive of en-
dothelial activation [17]. We further substantiated this
observation by an intravital microscopic approach in
which we showed that the endothelium of conventional
PDF-treated rats was activated compared to control rats
as manifested by a three-fold increase in the number of
rolling leukocytes [20].
Several groups also have reported an enhanced fibrotic
reaction upon exposure to conventional PDF [21, 22].
After four weeks of daily infusion of a lactate-based
solution containing 3.86% glucose, Margetts et al [21]
found significant changes in the rat peritoneum, includ-
ing submesothelial thickening, increased collagen depo-
sition, and an increase in vessel number and density.
We also found a two-fold increase in the submesothelial
matrix layer of the parietal peritoneal wall by light micro-
scopic evaluation [17]. We recently developed an electron
microscopy–based approach to measure peritoneal fibro-
sis by means of quantitative morphometric analysis of
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Fig. 1. Peritoneal fibrosis is quantified by
morphometry using electronmicrographs of
mesenteries of (A) control and (B) conven-
tional peritoneal dialysis fluid (PDF)-treated
rats. Arrows indicate the thickness of the sub-
mesothelial extracellular matrix layer. Note
the increase in mesenteric width in B. Bar
length is 10 lm.
Fig. 2. Light micrograph of abdominal peritoneal wall of a conven-
tional peritoneal dialysis fluid (PDF)-treated rat. Note the occurrence
of granulation tissue as depicted by an enormous increase in subme-
sothelial matrix as seen in the van Giesson staining.
the thickness of the submesothelial matrix of the mesen-
teries. Utilizing this technique we were able to show
a two-fold rise in fibrotic thickness of the mesentery af-
ter five to 10 weeks of exposure to conventional PDF
(Fig. 1). Focal formation of granulation tissue on the pari-
etal peritoneal wall also was observed. This granulation
tissue was characterized by a 10- to 20-fold thickening
of the submesothelial matrix, massive new vessel forma-
tion, and the presence of an infiltrate (Fig. 2). Injury to the
mesothelium was evidenced by a partial or complete loss
of the microvilli, and vacuolization and condensation of
the nucleus of mesothelial cells, with areas of complete
loss of the mesothelium. In many cases, these denuded
areas were covered by macrophages (Fig. 3), which rep-
resent a first line response to serosal damage. In addition
Fig. 3. Omental tissue of a conventional peritoneal dialysis fluid
(PDF)-treated rat. The mesothelial cells (MC) are partly present, partly
lost. On denuded areas, macrophages (indicated by arrows) try to cover
the serosal wound. Bar length is 10 lm.
to mesothelial cell loss, the remaining mesothelial cells
showed a regenerative healing response; mesothelial cell
density on liver imprints increased from ∼1000 cells/mm2
in control rats to 1200 to 1500 cells/mm2 in conventional
PDF-treated rats [16, 17].
Immunologic changes
Chronic exposure to conventional PDF induces a
strong milky spot response in the omentum. Milky spots
can be defined as local aggregates of immune cells, and
are formed in response to peritoneal inflammatory stim-
uli. In addition, the peritoneal leukocyte differential
cell count changed upon chronic PDF infusion. Mast
cells completely disappeared from peritoneal dwells and
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accumulated in the omentum. A low percentage of neu-
trophils and lymphocytes was observed in the peritoneal
dwell, but not seen in control. Most importantly, peri-
toneal cells that were exposed to PDF were clearly
hindered in their bacterial clearing capacity, which has
important implications for local peritoneal host defense
mechanisms [17].
Role of individual factors present in PDF
It is clear that exposure to the standard, acidic pH,
lactate-buffered PDF leads to significant alterations in
normal peritoneal membrane structure and function.
While bioincompatible factors in PD solutions have been
identified (e.g., acidic pH, lactate buffer, high glucose,
and GDP content), the exact mechanism by which these
contribute, individually or in combination, to the changes
that occur in patients on long-term PD remains unclear.
Are all of the changes caused by glucose, per se? What is
the role, if any, of GDPs? How does solution acidity af-
fect membrane physiology, and does the lactate content in
the presence of low pH create a hypoxic environment? To
begin to answer these questions, we investigated the con-
tribution of low pH, lactate buffer, high glucose concen-
tration, and GDPs to peritoneal injury in a rat chronic
exposure model [23]. Animals received a daily infusion
of either lactate buffer (Lac), a heat-sterilized, lactate-
based, 3.86% glucose PDF (HPD), or a filter-sterilized,
lactate-based, 3.86% solution (FPD). The HPD and FPD
solutions were identical except for the lower GDP con-
tent of the filter-sterilized solution; the Lac solution
lacked both glucose and GDPs. The pH of all solutions
was 5.2, and untreated animals served as control.
We already have reported that the presence of a peri-
toneal catheter without fluid instillation yields a small
but significant angiogenic response in the mesentery
[20]. Daily instillation of low pH lactate buffer alone
induced relatively mild changes, including damage to
and regeneration of the mesothelial cell layer (mea-
sured by mesothelial cell density on liver imprints),
increased hyaluronan levels in peritoneal effluent, in-
creases in milky spot number and total area (Fig. 4),
and mild angiogenesis in various tissues (Fig. 5). Treat-
ment with FPD (i.e., the addition of glucose to the lactate
buffer) strengthened most, but not all of these responses,
with a significantly increased fibrotic response and in-
creased number of omental vessels. Damage was most
severe in the standard PDF (SPD) group, with a further
increase in the number and size of milky spots (Fig. 4),
parietal blood vessels (Fig. 5), loss of mesothelial cell in-
tegrity, and the number of Fc-receptor–positive cells. We
conclude that low pH lactate results in mild perturba-
tions of peritoneal membrane physiology, that GDPs fur-
ther affect immunologic parameters (e.g., milky spots)
and mesothelial cells, with glucose involved mainly in
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Fig. 4. Graphic representation of the number of milky spots, the size of
the milky spots, as well as the total milky spot area, which indicates the
percentage of the omental surface that is covered by milky spots. ∗Heat-
sterilized peritoneal dialysis fluid (PDF) vs. the three other groups,
P < 0.03; #filter-sterilized PDF vs. heat-sterilized PDF and vs. control,
P < 0.03; $lactate buffer vs. heat-sterilized PDF and vs. control, P <
0.03. Reproduced with permission from Zareie et al [23].
fibrosis and angiogenesis. These observations indicate
that individual constituents of solutions may have diverse
effects on peritoneal membrane structure, and that over-
all response to PDF is a cumulative damage reaction
driven by various determinants.
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Fig. 5. Graphic representation of the number of omental, mesenteric
and abdominal wall vessels. This graph clearly illustrates that the var-
ious peritoneal tissues respond differently to the different peritoneal
dialysis (PD) solutions. ∗Heat- and filter-sterilized peritoneal dialysis
fluid (PDF) vs. lactate buffer and control, P < 0.04; #heat-sterilized and
filter-sterilized PDF and lactate buffer vs. control, P < 0.008; $heat-
sterilized PDF vs. control, P < 0.02. Reproduced with permission from
Zareie et al [23].
Aminoguanidine has been used to further assess the
role of GDPs in tissue injury. This drug can scavenge
GDPs, block the formation of AGEs downstream of
Amadori products, and inhibit inducible nitric oxide syn-
thase [24]. Using this approach in experimental diabetes
studies, the beneficial effects of aminoguanidine have
been established. Lee et al [25] added aminoguanidine
to standard PDF and were able to demonstrate after
12 weeks of exposure in a rat model that mesothelial
denudation was largely prevented, submesothelial mono-
cyte infiltration and capillary formation was not as promi-
nent, and AGE staining was reduced. This observation
is consistent with our observations on a possible role
for GDPs in mesothelial cell damage and loss [23]. In
addition, we were able to demonstrate that the supple-
mentation of conventional PDF with aminoguanidine
reduced endothelial activation and peritoneal fibrosis
(unpublished results). Taken together, these studies sug-
gest a role for GDPs in peritoneal membrane damage,
and imply that reduction of GDPs in PDF would result
in a more biocompatible fluid and preservation of mem-
brane physiology.
Biocompatibility studies with bicarbonate-based PDF
The manufacture of more biocompatible solutions with
a bicarbonate buffer system, neutral pH, and reduced
levels of GDPs was facilitated by the development of a
solution sterilization process using multichamber bags.
In these systems, glucose is heat-sterilized in a separate
compartment(s) at a low pH, which minimizes the de-
velopment of GDPs. The other compartment contains a
bicarbonate-buffered electrolyte solution. Immediately
prior to use, the contents of the chambers are mixed
and the resulting solution is a bicarbonate-buffered PDF
with a physiologic pH. A number of studies have evalu-
ated the in vivo biocompatibility of these new solutions.
Table 1 contains a compilation of published acute and
chronic animal studies performed with bicarbonate- or
bicarbonate/lactate-buffered PDF.
Acute experiments (i.e., with exposure times of less
than 24 hours) have been performed in order to study the
direct effects of bicarbonate-buffered PDF on peritoneal
transport, appetite, and microcirculation. These data all
support a preservation of function, an absence of vasodi-
lation of peritoneal arterioles [26], and an improvement
in ultrafiltration [27, 28], appetite [29], and leukocyte re-
cruitment [30] with bicarbonate-buffered PDF in contrast
to lactate-buffered PDF.
A variety of chronic exposure studies have been car-
ried out in which solution biocompatibility was eval-
uated over four- to 12-week periods. In two separate
experiments, we compared the peritoneal response to a
conventional acidic (pH 5.2), heat-sterilized, 40 mmol/L
lactate-buffered, 3.86% glucose PDF with a newer
neutral pH (pH 7.4), two-chamber, heat-sterilized,
25 mmol/L bicarbonate/15 mmol/L lactate-buffered,
3.86% glucose PDF (Physioneal 40, Baxter Health-
care Corporation, McGaw Park, IL, USA). Various
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Table 1. Published studies comparing bicarbonate (Bic)-, bicarbonate/lactate (Bic/Lac)-, and lactate-buffered (Lac) PDF in experimental PD
models
Author, year Ref. Species Study design Parameters Main results
Acute experiments
Yatzidis, 1993 [27] Rabbit Bic/glycylglycine vs. Lac 40 ml/
kg body weight 2–6 hours
Physiology peritoneum Bic/glycylglycine PDF yielded:
Increased ultrafiltration
Decreased glucose absorption
Increased phosphatidylserine
Musi, 1998 [28] Rat Various filter-sterilized PDF vs.
Lac 16 mL 4 hours
Peritoneal transport Combination of low pH and GDPs
caused increase in peritoneal small
solute transport
Zheng, 2001 [29] Rat Bic/Lac vs. Lac 30 mL 0.5 and
2 hours
Appetite Bic/Lac PDF yielded improved appetite
Mortier, 2002 [26] Rat Various fluids vs. Lac
Superfusion mesentery
Vasoactive effects on
mesenteric microcirculation
GDPs in PDF induced vasodilation of
mesenteric arteries
Mortier, 2003 [30] Rat Bic vs. Lac Superfusion
mesentery after peritoneal
infection
Leukocyte recruitment Bic PDF showed improved leukocyte
recruitment
Chronic experiments
Schambye, 1992 [33] Rabbit Bic vs. Lac 3 × 30 mL/day +
drain 4 weeks
Intraperitoneal catheter and
port
Peritonitis rate Histology No differences in peritonitis rate and
morphology of peritoneal tissues
Gotloib, 1996 [31] Mouse Bic vs. control 5 mL/day 2–30
days
Daily iintraperitoneal
injections
Morphology mesothelium Bic PDF yielded improved quality of
adaptation and survival of exposed
mesothelium compared to Lac (in
earlier study)
Di Paolo, 1996 [35] Rabbit Bic vs. Lac 120 mL/day + drain
30 days
Exteriorized IP Catheter
Morphology washed out
mesothelial cells
Bic PDF yielded no improvement in
mesothelial cells
Glucose was the major bioincompatible
factor
Suzuki, 1996 [33] Rat Bic vs. Lac 2 × 30 mL/day 4
weeks
Exteriorized IP catheter
Peritoneal transport on days 8
and 36 Histology
Bic PDF yielded:
Increased permeability
Reduction of fibrosis
Wieczorowska-Tobis, [37] Rat Bic/glycylglycine vs. Lac 2 ×
20 mL/day 4 weeks
Exteriorized intraperitoneal
catheter
Peritoneal transport on days 1
and 28 Histology
Bic/glycylglycine PDF yielded:
Decreased glucose reabsorption and
increased hyaluronan at day 1
Less transperitoneal protein leakage at
4 weeks
No differences in morphology
1997
Pawlaczyk, 1999 [34] Rat Bic/Lac vs. Lac 2 × 20 mL/day
4 weeks
Exteriorized intraperitoneal
catheter
Peritoneal transport days 28
(−LPS) and 29 (+LPS)
Peritoneal defense
Bic/Lac PDF yielded:
No differences in peritoneal transport
Diminished nonspecific inflammatory
response
Increased production of inflammatory
cytokines after LPS
Park, 2000 [32] Rat Bic/Lac vs. Lac 30 mL/day 12
weeks
Daily intraperitoneal injections
Peritoneal transport at week
12 Histology
AGE accumulation
Bic/Lac PDF yielded:
Improved ultrafiltration
Decreased AGE accumulation
Decreased mesothelial cell damage
Hekking, 2001 [17] Rat Bic/Lac vs. Lac 10 mL/day
9–10 weeks
Intraperitoneal catheter and
port
Peritoneal defense Histology Bic/Lac PDF yielded:
Reduction angiogenesis and milky spot
response
Improved mesothelial cell morphology
Improved ex vivo bacterial killing by
peritoneal leukocytes
Abbreviations are: AGE, advanced glycation end products; GDP, glucose degradation products; LPS, lipopolysaccharide; PDF, peritoneal dialysis fluid.
morphologic (e.g., new vessel formation, fibrosis,
mesothelial cell damage) as well as immunologic (e.g.,
milky spots, bacterial killing by peritoneal cells) param-
eters were analyzed [17]. Electron micrographs of rep-
resentative omental tissue from rats treated for nine
to 10 weeks with conventional PDF (Fig. 6A) or the
new bicarbonate/lactate-buffered PDF (Fig. 6B) are pre-
sented. The mesothelial cell layer was extensively dam-
aged in the standard solution group. This layer was better
preserved in the bicarbonate/lactate group, although the
mesothelial cells were flattened with a loss of microvilli
compared to the control. In contrast to the rats treated
with the bicarbonate/lactate-buffered solution, the en-
dothelial cells of the vessels observed in the milky spots of
standard solution-treated animals were greatly enlarged,
similar to high endothelial venules, suggesting a highly
activated endothelium. Moreover, in both experiments
we demonstrated that, compared to the conventional
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Fig. 6. Electronmicrographs of omental tissue from rats treated
with (A) conventional peritoneal dialysis fluid (PDF) or with (B)
bicarbonate/lactate-buffered PDF. Note the dramatic mesothelial cell
morphology and the endothelial cell activation in (A), which is not seen
in (B). Bar length is 20 lm. Reproduced with permission from the J Am
Soc Nephrol [17].
PDF, the bicarbonate/lactate-buffered PDF significantly
reduced the formation of new omental blood vessels
2.2- and 3.8-fold, respectively. Furthermore, after expo-
sure to bicarbonate/lactate-buffered PDF, a significant
50% to 75% reduction was found in the number and size
of omental milky spots. These results indicate that the new
PDF evoked much less peritoneal activation compared to
the conventional lactate-buffered PDF. Functionally, we
were able to demonstrate an improved ex vivo bacterial
clearance capacity of peritoneal macrophages [17], as il-
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Fig. 7. Bacterial killing of peritoneal cells recovered from rats after
daily instillation of conventional lactate-buffered peritoneal dialysis
fluid (PDF) (L) and bicarbonate/lactate-buffered PDF (B/L). C rep-
resents the killing of control peritoneal cells. Data are expressed as me-
dian and range. Control vs. B/L, P < 0.05; L vs. B/L, P < 0.05. Reprinted
with permission from the J Am Soc Nephrol [17].
lustrated in Figure 7. We thus concluded that the neutral
pH, bicarbonate/lactate PDF better preserves peritoneal
membrane physiology compared to conventional acidic,
lactate-based PDF.
These findings of improved biocompatibility of
bicarbonate-based solutions are consistent with those of
several other animal studies. In chronic peritoneal ex-
posure studies, mesothelial viability and integrity of the
peritoneal membrane examined by Trypan blue staining
and by assessment of mesothelial denudation, was im-
proved in a murine model after a 30-day exposure to
bicarbonate-buffered PDF [31] and in a rate model after
a 12-week exposure to bicarbonate/lactate-buffered PDF
[32]. In the latter study, Park et al [33] also observed less
AGE staining in the peritoneum of rats exposed to bicar-
bonate/lactate solution versus the lactate alone solution,
presumably due to the lower GDP content. In two other
short-term studies, rats receiving bicarbonate-buffered
solutions showed a reduction in peritoneal fibrosis after
four weeks, as suggested by the means of the total histo-
logic score by light microscopy and a diminished nonspe-
cific inflammatory response and increased production of
inflammatory cytokines upon lipopolysaccharide (LPS)
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challenge [34]. Several other studies, however, did not
find any differences in mesothelial morphology between
both types of fluid [35–37].
Schambye et al [36] found that the peritonitis rate
was not different between rabbits that had been treated
for four weeks with lactate- versus bicarbonate-buffered
PDF. However, the severity of peritonitis was signifi-
cantly greater in the lactate group. Likewise, the dialysate
leukocyte count declined significantly only in the lactate
group.
Peritoneal transport characteristics were evaluated in
animals exposed to bicarbonate-based solutions. Park
et al [32] demonstrated in a rat model that peri-
toneal ultrafiltration decreased after 12 weeks’ expo-
sure to conventional PDF, but that ultrafiltration was
preserved to a greater extent after administration of
a neutral bicarbonate/lactate-buffered PDF. Contrast-
ing results, however, were reported by Suzuki et al
[33], who showed an increased glucose absorption along
with decreased creatinine and protein clearance with
bicarbonate-buffered PDF after four weeks, which sug-
gest an increased peritoneal permeability compared to
conventional lactate-buffered PDF [30]. Wieczorovska
et al [37] suggested reduced transperitoneal protein trans-
port after four weeks’ treatment with a bicarbonate-
buffered PDF. However, Pawlaczyk et al [34] were not
able to show any differences in peritoneal transport be-
tween bicarbonate/lactate- and lactate-buffered PDF in
their four-week study in rats. Therefore, at present, there
is no outright consensus on whether peritoneal transport
physiology in chronic peritoneal exposure animal models
is improved by bicarbonate-buffered PDF, but the data
suggests that changes in transport status may be depen-
dent on time of exposure. The duration of several of the
studies was relatively short (four weeks), which might be
too short of a period to see a definitive change in trans-
port. Significantly longer studies (e.g., 12 weeks or more)
may be required to establish bona fide results.
CONCLUSION
Observations derived from animal peritoneal infusion
models show that the individual solution factors, in-
cluding glucose, GDPs, and buffer content, can differ-
entially affect peritoneal membrane biology and likely
act in an additive or synergistic manner. Based on re-
sults of preclinical peritoneal infusion animal models,
we conclude that the new generation of two-chamber,
bicarbonate/lactate-buffered PDF is more biocompat-
ible than conventional PDF. Emerging clinical data
with the newer solutions appear to support the ob-
servations from animal models by showing improved
peritoneal performance characteristics [38–40]. These re-
sults are very promising and warrant further clinical
evaluation.
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